# Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

> **NCT01021852** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 326 (actual)

## Conditions studied

- Primary Insomnia

## Interventions

- **DRUG:** MK-6096
- **DRUG:** Dose-matched Placebo to MK-6096

## Key facts

- **NCT ID:** NCT01021852
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-30
- **Primary completion:** 2011-02-01
- **Final completion:** 2011-02-01
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021852, "Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01021852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*